# To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

> **NCT01768572** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 202 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** sarilumab SAR153191 (REGN88)
- **DRUG:** tocilizumab
- **DRUG:** hydroxychloroquine
- **DRUG:** methotrexate
- **DRUG:** sulfasalazine
- **DRUG:** leflunomide
- **DRUG:** subcutaneous placebo
- **DRUG:** intravenous placebo

## Key facts

- **NCT ID:** NCT01768572
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2017-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01768572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01768572, "To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01768572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*